Overview
Portfolio
More
Ucb Ventures
Brussels, Belgium
Focus on biotech innovations addressing severe CNS and immunological conditions, emphasizing real-world patient value.
Portfolio
11+
Employees
1000+
Founded
1928
AUM
N/A
Investment focus
Stages
No stages listed
Industries
No industries listedGeographic scope
BelgiumUnited KingdomUnited States
Sources
Ucb Ventures
Focus on biotech innovations addressing severe CNS and immunological conditions, emphasizing real-world patient value.
Portfolio
11+
Employees
1000+
Founded
1928
AUM
N/A
Stages
No stages listed
Industries
No industries listedGeographic scope
BelgiumUnited KingdomUnited States
Sources
Showing 8 of 8 matched portfolio companies
Code Biotherapeutics is developing a multivalent synthetic DNA delivery platform, 3DNA®, to enhance the precision and bioavailability of non-viral gene therapies for life-threatening diseases. The company focuses on overcoming challenges such as dose-related toxicity and off-target effects, with a primary research emphasis on Duchenne Muscular Dystrophy.
Funding: $85.0M
Rough estimate of the amount of funding raised
Funding: $85.0M
Rough estimate of the amount of funding raised
ExeVir develops novel antibody therapies utilizing a modular platform based on camelid antibody fragments (VHH) for infectious disease control. This technology creates stable, cost-effective therapeutic compounds capable of binding multiple conserved epitopes on pathogens. The company is advancing a pipeline focused initially on COVID-19 and dengue to address public health threats, particularly for vulnerable patient populations.
Funding: $76.6M
Rough estimate of the amount of funding raised
Funding: $76.6M
Rough estimate of the amount of funding raised
Iris Medicine is developing small binding RNAs (sbRNAs) that selectively target expanded repeat sequences in mRNA to inhibit the expression of mutant genes associated with repeat expansion disorders. This technology aims to provide effective treatments for conditions like Huntington’s Disease and C9orf72 ALS, where current therapeutic options are limited.
Funding: $400.0K
Rough estimate of the amount of funding raised
Funding: $400.0K
Rough estimate of the amount of funding raised
Rinri Therapeutics is developing engineered stem cell therapies specifically for the regeneration of auditory tissues affected by sensorineural hearing loss. This approach aims to restore hearing functionality and improve patient quality of life by addressing the underlying cellular damage caused by various auditory conditions.
Funding: $21.1M
Rough estimate of the amount of funding raised
Funding: $21.1M
Rough estimate of the amount of funding raised
Seamless Therapeutics develops disease-modifying gene editing candidates using programmable recombinase technology. This approach enables precise, large DNA edits within the genome without introducing unintended mutations. The company aims to expand the therapeutic potential of gene editing to treat severe genetic diseases.
Funding: $25.0M
Rough estimate of the amount of funding raised
Funding: $25.0M
Rough estimate of the amount of funding raised
Switch Therapeutics develops precision neuroscience medicines using its proprietary Conditionally Activated siRNA (CASi) platform. This technology combines features of ASOs and siRNAs into a single molecule for efficient self-delivery and potent knockdown. The CASi platform enables cell-selective targeting to improve therapeutic windows for treating central nervous system diseases.
Funding: $68.0M
Rough estimate of the amount of funding raised
Funding: $68.0M
Rough estimate of the amount of funding raised
ViaNautis develops polyNaut®, a proprietary nanovesicle platform that utilizes advanced polymer materials and machine learning to deliver nucleic acid therapeutics with high precision to targeted tissues and cell types. This technology addresses the challenge of safely and effectively delivering genetic medicines, such as mRNA and siRNA, to treat previously untreatable diseases.
Funding: $28.5M
Rough estimate of the amount of funding raised
Funding: $28.5M
Rough estimate of the amount of funding raised
Walden Biosciences is developing targeted gene editing therapies to modify renal cell function in patients with chronic kidney disease. This approach aims to improve patient outcomes by reducing reliance on dialysis and kidney transplants.
Funding: $51.0M
Rough estimate of the amount of funding raised
Funding: $51.0M
Rough estimate of the amount of funding raised
Showing 3 of 3 unmatched portfolio companies